Key Points
- CEO Neil Mcfarlane sold 20,000 shares of Zevra Therapeutics at an average price of $11.25, generating $225,000. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 417,225 shares.
- Zevra shares opened at $10.39, down 8.2%, with a market capitalization of approximately $617 million. The stock has traded between $8.01 and $15.03 over the past year.
- Analysts maintain a broadly positive outlook, with a consensus “Buy” rating and an average price target of $27.14. The company also exceeded quarterly expectations, reporting $0.25 in EPS versus an $0.11 consensus estimate and revenue of $39.66 million.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) CEO Neil Mcfarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the transaction, the chief executive officer directly owned 417,225 shares of the company's stock, valued at $4,693,781.25. The trade was a 4.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Zevra Therapeutics Stock Down 8.2%
Zevra Therapeutics stock opened at $10.39 on Wednesday. The company's 50-day moving average price is $11.54 and its 200-day moving average price is $11.41. The company has a market cap of $616.96 million, a PE ratio of 7.16 and a beta of 0.98. Zevra Therapeutics, Inc. has a twelve month low of $8.01 and a twelve month high of $15.03.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. As a group, sell-side analysts expect that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
ZVRA has been the subject of several analyst reports. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Sunday, July 12th. Citizens Jmp lifted their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a "market outperform" rating in a report on Thursday, August 6th. Weiss Ratings reissued a "hold (c)" rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th. William Blair raised Zevra Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. Finally, Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $29.00 to $20.00 and set a "buy" rating on the stock in a report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $27.14.
Read Our Latest Research Report on Zevra Therapeutics
Institutional Trading of Zevra Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC bought a new stake in Zevra Therapeutics in the first quarter worth about $11,184,000. Hennion & Walsh Asset Management Inc. boosted its position in shares of Zevra Therapeutics by 116.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company's stock valued at $5,502,000 after buying an additional 206,543 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company's stock valued at $5,168,000 after buying an additional 400,336 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Zevra Therapeutics during the second quarter valued at approximately $2,846,000. Finally, Globeflex Capital L P bought a new position in shares of Zevra Therapeutics during the second quarter valued at approximately $2,752,000. 35.03% of the stock is owned by hedge funds and other institutional investors.
Zevra Therapeutics Company Profile
(
Get Free Report)
Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.
Zevra's lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
